HENGRUI PHARMA(01276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.47 billion, YoY increase of 0.34%

NewTimeSpace News: August 19, 2026, HENGRUI PHARMA(01276.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 15.46 billion, decreased by 1.94% YoY; Net Profit stood at CNY 4.47 billion, YoY increase of 0.24%; Profit Attributable to Shareholders stood at CNY 4.47 billion, YoY increase of 0.34%; Basic Earnings Per Share (EPS) stood at CNY 0.68.

In terms of profitability, HENGRUI PHARMA Gross Profit changed from CNY 13.65 billion in the same period last year to CNY 13.34 billion in the current period, decreased by CNY 303.99 million; gross profit margin changed from 86.58% in the same period last year to 86.33% in the current period, decreased by 0.25 percentage points; net profit changed from CNY 4.45 billion in the same period last year to CNY 4.47 billion in the current period, increased by CNY 10.61 million; net profit margin changed from 28.26% in the same period last year to 28.89% in the current period, increased by 0.63 percentage points. 

In terms of earnings quality, HENGRUI PHARMA Operating Profit changed from CNY 5.1 billion in the same period last year to CNY 5.03 billion in the current period, decreased by CNY 76.53 million; Operating Profit Margin changed from 32.38% in the same period last year to 32.53% in the current period, increased by 0.15 percentage points; Net Cash Flow from Operating Activities changed from cash inflow of CNY 4.3 billion in the same period last year to cash inflow of CNY 1.99 billion in the current period, decreased by CNY 2.31 billion; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from 27.29% in the same period last year to 12.86% in the current period, decreased by 14.43 percentage points. 

In terms of financial soundness, HENGRUI PHARMA Debt-to-Asset Ratio changed from 6.14% in the same period last year to 8.17% in the current period, increased by 2.03 percentage points; Total Equity changed from CNY 59.03 billion in the same period last year to CNY 64.99 billion in the current period, increased by CNY 5.96 billion; Cash and Cash Equivalents changed from CNY 35.543 billion in the same period last year to CNY 38.032 billion in the current period, increased by CNY 2.49 billion; Current Liabilities changed from CNY 3.47 billion in the same period last year to CNY 4.25 billion in the current period, increased by CNY 782.17 million; Quick Ratio changed from 12.75 in the same period last year to 10.98 in the current period, decreased by 1.77 percentage points. 

In terms of R&D investment focus, HENGRUI PHARMA R&D Expenses changed from CNY 3.23 billion in the same period last year to CNY 3.49 billion in the current period, increased by CNY 264.98 million; R&D to Total Revenue Ratio changed from 20.48% in the same period last year to 22.6% in the current period, increased by 2.12 percentage points. 

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.